EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study

Huilin Tang iD, Yiwen Lu, Bingyu Zhang, Ting Zhou, Dazheng Zhang, Jiajie Chen, Yong Chen, David A Asch, Yong Chen

Diabetes, Obesity and Metabolism · 2025-11 · 27 (11) · 6527-6536

DOI: 10.1111/dom.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.08.2025. Verfasst von Huilin Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Cardiovascular Diseases, Anti-Obesity Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CLC NIH HHS, NIDDK NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide‐1 receptor agonists ( GLP ‐ 1RAs ) provide cardiovascular and renal benefits in type 2 diabetes, but their real‐world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP ‐ 1RAs versus other anti‐obesity medications ( AOMs ) in adults with obesity. Materials and Methods This target trial emulation used TriNetX electronic health records (July 2021–May 2025) to identify adults with obesity and no diabetes history who initiated GLP ‐ 1RAs (liraglutide, semaglutide, or tirzepatide) or other AOMs . Outcomes included major adverse cardiovascular events ( MACE ), major adverse kidney events ( MAKE ), all‐cause mortality, mental health conditions, and safety outcomes. Propensity score matching (1:1) balanced baseline characteristics; Cox models estimated hazard ratios ( HRs ) with 95% confidence intervals ( CIs ).

Results

The study included 140 169 matched pairs of GLP ‐ 1RA and AOM initiators. Mean follow‐up was 392 days for GLP ‐ 1RA users and 564 days for AOM users. Compared to AOMs , GLP ‐ 1RA use was associated with lower risks of MACE ( HR , 0.76; 95% CI , 0.72–0.81), MAKE ( HR , 0.64; 95% CI , 0.55–0.74), and all‐cause mortality ( HR , 0.49; 95% CI , 0.42–0.57). Mental health outcomes also improved, with reduced risks of depression ( HR , 0.63), suicidal ideation/attempt ( HR , 0.42), and substance use disorder ( HR , 0.58). GLP ‐ 1RAs were not associated with increased risks of acute pancreatitis ( HR , 1.17), hypoglycemia ( HR , 1.08), or gastrointestinal symptoms ( HR , 0.99).

Conclusions

Among adults with obesity but without diabetes, GLP ‐ 1RA use was associated with reduced cardiovascular, kidney, mortality, and mental health risks compared to other AOMs .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityCardiovascular DiseasesAnti-Obesity AgentsHypoglycemic AgentsKidney DiseasesHumansMaleFemaleMiddle AgedAdultLiraglutideDiabetes Mellitus, Type 2Glucagon-Like PeptidesTreatment OutcomeAgedKidneyGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1 receptor agonistsanti‐obesity medicationmajor adverse cardiovascular eventsmajor adverse kidney events

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideAnti-Obesity AgentsGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Pfizer Inc., New York City, New York, USA.
  • Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Huilin Tang

Förderung

  • CLC NIH HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • NLM NIH HHS
  • NIMH NIH HHS
  • NEI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Tang, H., Lu, Y., Zhang, B., Zhou, T., Zhang, D., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2025). Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes, Obesity and Metabolism, 27(11), 6527-6536. https://doi.org/10.1111/dom.70054

Vancouver

Tang H, Lu Y, Zhang B, Zhou T, Zhang D, Chen J, et al. Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes, Obesity and Metabolism. 2025;27(11):6527-6536. doi:10.1111/dom.70054

BibTeX
@article{Tang2025,
  author = {Tang, Huilin and Lu, Yiwen and Zhang, Bingyu and Zhou, Ting and Zhang, Dazheng and Chen, Jiajie and Chen, Yong and Asch, David A and Chen, Yong},
  title = {Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {11},
  pages = {6527--6536},
  doi = {10.1111/dom.70054}
}
Kostenlos starten →